Сd10 + b淋巴细胞和浆细胞与乳腺癌预后的相关性

IF 1.6 Q3 HEMATOLOGY

Hematology, Transfusion and Cell Therapy Pub Date : 2025-07-01 DOI:10.1016/j.htct.2025.103920

Svetlana Chulkova

{"title":"Сd10 + b淋巴细胞和浆细胞与乳腺癌预后的相关性","authors":"Svetlana Chulkova","doi":"10.1016/j.htct.2025.103920","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Bone Marrow (BM) is poorly understood from the point of view of the prognostic role of hematopoietic cells and subpopulations of lymphocytes in patients with Breast Cancer (BC). In recent years, more attention has been paid to the study of the innate immune system, which includes B-lymphocytes. They produce IgM antibodies, which play an important role in the induction of apoptosis.</div></div><div><h3>Methodology</h3><div>Study was carried out in 107 BC patients’ stage I‒II. Adjuvant chemotherapy ‒ 65.4% of patients, radiation therapy ‒ 49.8%, hormone therapy ‒ 84% of patients. Her2/neu\"-\" 80%, Her2/neu\"+\"-18%, TNBC-12%. The duration of the follow-up period after surgery was 8-years. Multiparameter flow cytometry was used, FACSCANTO II. Studies of BM lymphocyte subpopulations were carried out in the gate of CD45++ cells: CD19, CD20, CD5, CD38, CD10, CD45, HLA-DR, CD27. Radical resection -38.3% of patients, mastectomy ‒ 59.7%.</div></div><div><h3>Results</h3><div>B1-cells was higher in B-Her2\"+\", stage IIA, with 2 affected lymph nodes. B1-cells correlated with plasma cells. The total percentage of B-cells in BM was significantly associated with the prognosis of BC. B1 cells were associated with progression-free and disease-free survival. Disease progression was observed at low levels of B1 cells. In cases more than 10% B-lymphocytes in the BM of BC patients’ Overall Survival (OS) rates were more favorable (p = 0.01). Especially for BC with a high Ki-67. Disease progression was observed in 1/3 of BC patients with low levels of B1 cells. CD38 expression on B-cells was a prognostically favorable factor: the role is realized during 5–10-years of follow-up after surgery. Level CD38+ B-cells more than 10% correlated with high OS (p = 0.02). The presence of CD10+CD19+ B-lineage precursors was associated with a more favorable prognosis (OS, the threshold level 12%, р = 0.04). The prognostic role of the CD10 antigen was realized when patients were observed for more than 5-years.</div></div><div><h3>Conclusion</h3><div>Total relative number of (more than 10%) of BM CD19+ cells were significantly related to OS in BC. B-cell precursors and CD38+ B-cells were associated with favorable prognosis. Prognostic role of B-lineage precursors and CD38- positive cells was in the periods of 5–10 years after surgery.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103920"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CORRELATION OF СD10+ B-LYMPHOCYTES AND PLASMA CELLS WITH OUTCOME IN BREAST CANCER\",\"authors\":\"Svetlana Chulkova\",\"doi\":\"10.1016/j.htct.2025.103920\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Bone Marrow (BM) is poorly understood from the point of view of the prognostic role of hematopoietic cells and subpopulations of lymphocytes in patients with Breast Cancer (BC). In recent years, more attention has been paid to the study of the innate immune system, which includes B-lymphocytes. They produce IgM antibodies, which play an important role in the induction of apoptosis.</div></div><div><h3>Methodology</h3><div>Study was carried out in 107 BC patients’ stage I‒II. Adjuvant chemotherapy ‒ 65.4% of patients, radiation therapy ‒ 49.8%, hormone therapy ‒ 84% of patients. Her2/neu\\\"-\\\" 80%, Her2/neu\\\"+\\\"-18%, TNBC-12%. The duration of the follow-up period after surgery was 8-years. Multiparameter flow cytometry was used, FACSCANTO II. Studies of BM lymphocyte subpopulations were carried out in the gate of CD45++ cells: CD19, CD20, CD5, CD38, CD10, CD45, HLA-DR, CD27. Radical resection -38.3% of patients, mastectomy ‒ 59.7%.</div></div><div><h3>Results</h3><div>B1-cells was higher in B-Her2\\\"+\\\", stage IIA, with 2 affected lymph nodes. B1-cells correlated with plasma cells. The total percentage of B-cells in BM was significantly associated with the prognosis of BC. B1 cells were associated with progression-free and disease-free survival. Disease progression was observed at low levels of B1 cells. In cases more than 10% B-lymphocytes in the BM of BC patients’ Overall Survival (OS) rates were more favorable (p = 0.01). Especially for BC with a high Ki-67. Disease progression was observed in 1/3 of BC patients with low levels of B1 cells. CD38 expression on B-cells was a prognostically favorable factor: the role is realized during 5–10-years of follow-up after surgery. Level CD38+ B-cells more than 10% correlated with high OS (p = 0.02). The presence of CD10+CD19+ B-lineage precursors was associated with a more favorable prognosis (OS, the threshold level 12%, р = 0.04). The prognostic role of the CD10 antigen was realized when patients were observed for more than 5-years.</div></div><div><h3>Conclusion</h3><div>Total relative number of (more than 10%) of BM CD19+ cells were significantly related to OS in BC. B-cell precursors and CD38+ B-cells were associated with favorable prognosis. Prognostic role of B-lineage precursors and CD38- positive cells was in the periods of 5–10 years after surgery.</div></div>\",\"PeriodicalId\":12958,\"journal\":{\"name\":\"Hematology, Transfusion and Cell Therapy\",\"volume\":\"47 \",\"pages\":\"Article 103920\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology, Transfusion and Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2531137925001889\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137925001889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

从造血细胞和淋巴细胞亚群在乳腺癌（BC）患者预后中的作用来看，骨髓（BM）尚不清楚。近年来，包括b淋巴细胞在内的先天免疫系统的研究受到越来越多的关注。它们产生IgM抗体，在诱导细胞凋亡中起重要作用。方法研究在107例I-II期BC患者中进行。辅助化疗占65.4%，放射治疗占49.8%，激素治疗占84%。Her2/neu“-”80%,Her2/neu“+”-18%,TNBC-12%。术后随访8年。采用多参数流式细胞仪FACSCANTO II。BM淋巴细胞亚群的研究以CD45++细胞为大门：CD19、CD20、CD5、CD38、CD10、CD45、HLA-DR、CD27。根治性切除-38.3%，乳房切除术- 59.7%。结果B-Her2“+”b1细胞增多，IIA期2个淋巴结受累。b1细胞与浆细胞相关。BM中b细胞的总百分比与BC的预后有显著相关性。B1细胞与无进展和无病生存相关。在低水平的B1细胞中观察到疾病进展。在BM中b淋巴细胞超过10%的情况下，BC患者的总生存率（OS）更有利（p = 0.01）。特别是对于Ki-67高的BC。在1/3的低水平B1细胞的BC患者中观察到疾病进展。b细胞上的CD38表达是预后有利因素：其作用在术后5 - 10年的随访中得以实现。CD38+ b细胞水平大于10%与高OS相关（p = 0.02）。CD10+CD19+ b系前体的存在与更有利的预后相关（OS，阈值水平12%， = 0.04）。当患者观察5年以上时，CD10抗原的预后作用才得以实现。结论BM CD19+细胞的总相对数量（大于10%）与BC的OS有显著相关性。b细胞前体和CD38+ b细胞与良好的预后相关。b系前体和CD38阳性细胞在术后5-10年的预后作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CORRELATION OF СD10+ B-LYMPHOCYTES AND PLASMA CELLS WITH OUTCOME IN BREAST CANCER

Objective

Bone Marrow (BM) is poorly understood from the point of view of the prognostic role of hematopoietic cells and subpopulations of lymphocytes in patients with Breast Cancer (BC). In recent years, more attention has been paid to the study of the innate immune system, which includes B-lymphocytes. They produce IgM antibodies, which play an important role in the induction of apoptosis.

Methodology

Study was carried out in 107 BC patients’ stage I‒II. Adjuvant chemotherapy ‒ 65.4% of patients, radiation therapy ‒ 49.8%, hormone therapy ‒ 84% of patients. Her2/neu"-" 80%, Her2/neu"+"-18%, TNBC-12%. The duration of the follow-up period after surgery was 8-years. Multiparameter flow cytometry was used, FACSCANTO II. Studies of BM lymphocyte subpopulations were carried out in the gate of CD45++ cells: CD19, CD20, CD5, CD38, CD10, CD45, HLA-DR, CD27. Radical resection -38.3% of patients, mastectomy ‒ 59.7%.

Results

B1-cells was higher in B-Her2"+", stage IIA, with 2 affected lymph nodes. B1-cells correlated with plasma cells. The total percentage of B-cells in BM was significantly associated with the prognosis of BC. B1 cells were associated with progression-free and disease-free survival. Disease progression was observed at low levels of B1 cells. In cases more than 10% B-lymphocytes in the BM of BC patients’ Overall Survival (OS) rates were more favorable (p = 0.01). Especially for BC with a high Ki-67. Disease progression was observed in 1/3 of BC patients with low levels of B1 cells. CD38 expression on B-cells was a prognostically favorable factor: the role is realized during 5–10-years of follow-up after surgery. Level CD38+ B-cells more than 10% correlated with high OS (p = 0.02). The presence of CD10+CD19+ B-lineage precursors was associated with a more favorable prognosis (OS, the threshold level 12%, р = 0.04). The prognostic role of the CD10 antigen was realized when patients were observed for more than 5-years.

Conclusion

Total relative number of (more than 10%) of BM CD19+ cells were significantly related to OS in BC. B-cell precursors and CD38+ B-cells were associated with favorable prognosis. Prognostic role of B-lineage precursors and CD38- positive cells was in the periods of 5–10 years after surgery.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊